• Today: November 02, 2025

win-medicare-ltd-v-dua-pharmaceuticals-ltd

02 November, 2025
251
Win-Medicare Ltd. v. DUA Pharmaceuticals — Deceptive Similarity in Pharma Marks | The Law Easy Skip to content

Win-Medicare Ltd. v. DUA Pharmaceuticals (P) Ltd.

Are “DICLOMOL” and “DICAMOL” so close that ordinary buyers may get confused? If yes, should the Court stop the use at once?

```
High Court of Delhi 1997 SCC OnLine Del 803 Trademark / Pharma India ~6–7 min read
AUTHOR_NAME: Gulzar Hashmi PUBLISH_DATE: 01 Nov 2025 LOCATION: India win-medicare-ltd-v-dua-pharmaceuticals-ltd
Case cover: DICLOMOL vs DICAMOL trademark dispute
```
PRIMARY_KEYWORDS: deceptive similarity; pharma trademarks; interim injunction; Order XXXIX CPC SECONDARY_KEYWORDS: DICLOMOL; DICAMOL; Pianotist test; passing off; Delhi High Court 1997

Quick Summary

Win-Medicare used the drug mark DICLOMOL. DUA began using DICAMOL. The Delhi High Court compared the two as an average buyer would and found a real risk of confusion. Applying Order XXXIX CPC (prima facie case, balance of convenience, irreparable harm), the Court restrained DUA from using DICAMOL or similar marks.

Issues

  • Are DICLOMOL and DICAMOL so similar that consumers and traders are likely to be confused?
  • Do Plaintiffs have a right to stop the Defendants from using DICAMOL through an interim injunction?

Rules

  • Order XXXIX Rules 1 & 2 CPC: Interim injunction needs (i) prima facie case, (ii) balance of convenience, (iii) irreparable injury.
  • Pianotist Test (Lord Parker): Compare marks by look, sound, and idea from the view of an average person with imperfect recollection.
  • Pharma context: even small confusion can harm public health; stricter approach to similarity.

Facts (Timeline)

view

1988: Plaintiff registers and markets anti-inflammatory drug as DICLOMOL; gains reputation and approvals.

1995: Plaintiff discovers DICAMOL in the market; issues notices fearing confusion and harm.

Response: Defendant says colour/batch differences remove confusion; denies similarity.

Suit & Hearing: Plaintiffs seek permanent and interim injunction before the Delhi High Court.

Timeline of events in Win-Medicare v. DUA

Arguments

Appellant / Plaintiff

  • DICAMOL is visually and phonetically close to DICLOMOL; likely confusion.
  • Decades of goodwill; misuse harms reputation and patients.
  • Injunction justified under Order XXXIX—urgent protection needed.

Respondent / Defendant

  • Marks differ; packaging/colour/batch numbers avoid confusion.
  • No intent to ride on Plaintiff’s reputation.
  • Injunction would cause greater hardship to the Defendant.

Judgment

Injunction Granted

The Court held the Plaintiffs showed a prima facie case. Balance of convenience and risk of irreparable injury were in their favour. Using the Pianotist test, the Court found likely confusion. Defendants and related authorities were restrained from manufacturing, selling, or marketing under DICAMOL or similar names.

  • Public interest in drug safety supported an immediate restraint.
  • Minor packaging differences do not cure name-level similarity.
Judgment highlight: injunction in Win-Medicare v. DUA

Ratio Decidendi

Where drug marks are phonetically/visually close, likely confusion is enough to justify an injunction. Under Order XXXIX CPC, if the Plaintiff shows a strong prima facie right and risk of irreparable harm, the Court must protect the mark at once.

Why It Matters

  • Sets a strict standard for pharma names—patient safety first.
  • Confirms swift relief using Order XXXIX when confusion is likely.
  • Reinforces the Pianotist approach for deceptive similarity.

Key Takeaways

  • Pharma marks need wider distance: sound + sight + idea.
  • Order XXXIX: show prima facie, balance, irreparable harm.
  • Packaging changes rarely fix name confusion.
  • Prefixes/suffixes in drug names can mislead—test rigorously.
  • Public interest strengthens injunctions in medicines.

Mnemonic + 3-Step Hook

P-I-L-LPhonetics, Idea, Look, Loss (irreparable).

  1. Hear it: Say both names aloud—do they sound close?
  2. See it: Compare spelling/structure for average buyers.
  3. Weigh it: Apply Order XXXIX—grant relief if harm looms.

IRAC Outline

Issue

Is DICAMOL deceptively similar to DICLOMOL, warranting an interim restraint?

Rule

Pianotist similarity test; Order XXXIX—prima facie, balance, irreparable injury.

Application

High phonetic/visual closeness; drug context heightens risk to public.

Conclusion

Interim injunction granted; use of DICAMOL restrained.

Glossary

Term Simple Meaning
Deceptive SimilarityTwo marks are so close that ordinary people may think they come from the same source.
Pianotist TestCompare look, sound, and idea of marks as an average person would.
Order XXXIX CPCLaw allowing temporary court orders to prevent harm before trial.
Prima Facie CaseBasic, first-look proof showing a real legal claim.
Irreparable InjuryHarm that money later cannot fully fix.

FAQs

Overall similarity in sight and sound of the names; the risk that ordinary buyers/pharmacists could mix them up.

Not usually. When names are close, buyers may be confused even before noticing packing or colour differences.

Confusion in medicines can risk health. Courts lean towards preventing any likely mix-up at an early stage.

It stopped the Defendants and related authorities from making, selling, or marketing under DICAMOL or any confusingly similar mark.

Reviewed by The Law Easy

Trademark Pharmaceutical Law Interim Relief
```
Timeline visual for Win-Medicare v. DUA
Judgment visual for Win-Medicare v. DUA
Win-Medicare Ltd. v. DUA Pharmaceuticals (P) Ltd. deceptive similarity; pharma trademarks; interim injunction; Order XXXIX CPC DICLOMOL; DICAMOL; Pianotist test; passing off; Delhi High Court 1997 2025-11-01 Gulzar Hashmi India win-medicare-ltd-v-dua-pharmaceuticals-ltd

Comment

Nothing for now